Similar Search Results

Expected Profits and the Scientific Novelty of Innovation

Dranove, David; Garthwaite, Craig; Hermosilla, Manuel - 2022

Innovation policy involves trading off monopoly output and pricing in the short run in exchange for incentives for …

Persistent link: https://www.econbiz.de/10013309194

The Future of Drug Development : The Economics of Pharmacogenomics

Vernon, John A.; Hughen, W. Keener; Vernon, John A. - 2021

This paper models how the evolving field of pharmacogenomics (PG), which is the science of using genomic markers to predict drug response, may impact drug development times, attrition rates, costs, and the future returns to research and development (R&D). While there still remains an abundance...

Persistent link: https://www.econbiz.de/10013311658

The Role of Assets in Place : Loss of Market Exclusivity and Investment

Higgins, Matthew John; Kronlund, Mathias; Park, Ji Min; … - 2022

We utilize a novel identification strategy to analyze the impact of assets in place on firms' decisions for future projects. We exploit the context in the pharmaceutical industry, where the loss of market exclusivity for a branded drug can be used to separate the impact of cash flows generated...

Persistent link: https://www.econbiz.de/10013406834

Private and Social Returns to R&D : Drug Development and Demographics

Benmelech, Efraim; Eberly, Janice; Krieger, Joshua; … - 2022

Investment in intangible capital—in particular, research and development—increased dramatically since the 1990s. However, productivity growth remains sluggish in recent years. One potential reason is that a significant share of the increase in intangible investment is geared toward consumer...

Persistent link: https://www.econbiz.de/10014264816

The Cost of Us Pharmaceutical Price Reductions : A Financial Simulation Model of R&D Decisions

Abbott, Thomas A.; Vernon, John A. - 2021

Previous empirical studies that have examined the links between pharmaceutical price controls, profits, cash flows, and investment in research and development (R&D) have been largely based on retrospective statistical analyses of firm- and/or industry-level data. These studies, which have...

Persistent link: https://www.econbiz.de/10013227913

Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-Income Countries, 2000-2009

Lichtenberg, Frank R. - 2014

I examine the impact of pharmaceutical innovation, as measured by the vintage (world launch year) of prescription drugs …

Persistent link: https://www.econbiz.de/10013065798

Short-Run Subsidies and Long-Run Adoption of New Health Products : Evidence from a Field Experiment

Dupas, Pascaline - 2014

Short-run subsidies for health products are common in poor countries. How do they affect long-run adoption? We present a model of technology adoption in which people learn about a technology's effectiveness by using it (or observing others using it) for some time, but people quit using it too...

Persistent link: https://www.econbiz.de/10013069397

Cost-Offsets of New Medications for Treatment of Schizophrenia

Frank, Richard G. - 2010

Broad claims are frequently made that new medications will offset all or part of their costs by reducing other areas of Medicaid spending. In this paper we examine the net impact on spending for new drugs used to treat schizophrenia. We extend research in this area by taking a new approach to...

Persistent link: https://www.econbiz.de/10012760589

The Impact of Pharmaceutical Innovation on Premature Cancer Mortality in Canada, 2000-2011

Lichtenberg, Frank R. - 2015

of decline across cancer sites. I analyze the effect that pharmaceutical innovation had on premature cancer mortality in … Canada during the period 2000-2011, by investigating whether the cancer sites that experienced more pharmaceutical innovation … that pharmaceutical innovation during the period 1985-1996 reduced the number of years of potential life lost to cancer …

Persistent link: https://www.econbiz.de/10013021477

Missing Novelty in Drug Development

Krieger, Joshua - 2018

This paper provides evidence that risk aversion leads pharmaceutical firms to underinvest in radical innovation. We …

Persistent link: https://www.econbiz.de/10012919316